Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
77.19 K
Value Traded
-
Short % Float
0.27%
+2.39%Week
-41.19%1 Month
+35.08%3 Month
+35.08%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
260.86 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
260.66 M
Total Shares
14.86 M
Float Shares
9.54 M
Insiders
35.75%
Institutions
12.95%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VOGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Vogenx Inc Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vogenx Inc Common Stock
5Total events
1Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 4
●Management ChangeCorporate
Ken Toombs appointed to Board of Directors as independent director and Audit Committee Chair
Past FDA Catalysts and PDUFA Decisions
How VOGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every VOGX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VOGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VOGX for Q2 2026. | ||||
VOGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VOGX ranks across every disease it competes in
Competitive Position is a premium feature
See how VOGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVOGX News
-VOGX
Oct 9, 2026▲ +0.4%today
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Vogenx, Inc. has appointed Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Gorman, who previously served on the Board of Directors, will lead commercial operations and corporate strategy as the company advances its lead product, mizagliflozin. His appointment is expected to enhance Vogenx's market development efforts for serious metabolic and gastrointestinal diseases.
Read more →-VOGX
Sep 22, 2026▼ -9.9%on this news· ran to -23% by day 3
Vogenx Appoints Ken Toombs to Board of Directors
Vogenx, Inc. has appointed Ken Toombs to its Board of Directors as an independent director and Chair of the Audit Committee. Toombs, who has over thirty years of experience in global professional services, will provide strategic guidance as the company scales its operations post-IPO. His background in healthcare and life sciences is expected to be invaluable for Vogenx's growth.
Read more →-VOGX
Aug 17, 2026Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Vogenx, Inc. successfully completed its initial public offering, raising $81.3 million by offering 6,250,000 shares at $13.00 each. The IPO closed on August 13, 2026, and Vogenx's stock began trading on the Nasdaq under the ticker VOGX. The company aims to advance therapeutics for metabolic dysfunction-related diseases.
Read more →About Vogenx Inc Common Stock
Headquarters3901 BARRETT DRIVE, SUITE 300, RALEIGH, NC, 27609
BIOPHARMAWATCH ELITE PLUS
Trade the next VOGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime